NCT04916509View on ClinicalTrials.gov

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

CompletedOBSERVATIONAL
Enrollment

258

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Breast Neoplasms
Interventions
DRUG

Palbociclib plus an aromatase inhibitor

Palbociclib plus an aromatase inhibitor therapy

DRUG

Palbociclib plus fulvestrant

Palbociclib plus fulvestrant

Trial Locations (7)

11426

King Abdulaziz Medical City National Guard Hospital Riyahd, Riyadh

11472

King Saud University Medical City Riyadh PO BOX 7805, Riyadh

22384

King Abdulaziz Medical City National Guard Hospital, Jeddah

Unknown

Hamad Medical Corporation, Doha

Tawam, Al Ain City

Dubai Hospital, Dubai

Mediclinic City Hospital, Dubai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04916509 - Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region | Biotech Hunter | Biotech Hunter